MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'american society of clinical oncology'. Sat, 03 Sep 2011 02:31:09 +0100 http://www.medworm.com/index.php?rid=4934740&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F11%2F2011-asco-exelixis-reports-expanded-cabozantinib-xl184-phase-ii-data-for-advanced-ovarian-cancer-six-deaths-reported%2F Exelixis, Inc. reported expanded Phase 2 study data with respect to cabozantinib (XL184) use in advanced ovarian cancer patients at the recent 2011 American Society of Clinical Oncology Annual Meeting. The overall solid tumor Phase 2 safety and tolerability data reference six deaths, including two ovarian cancer patients. Exelixis, Inc. reported expanded Phase 2 study [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4934740 Sat, 11 Jun 2011 16:10:03 +0100 4934740 http://www.medworm.com/index.php?rid=4921689&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F09%2F2011-asco-additional-phase-iii-study-data-support-the-potential-role-of-avastin-in-newly-diagnosed-recurrent-ovarian-cancer%2F Positive results from two bevacizumab (Avastin®) phase III clinical studies were presented at the 2011 American Society of Clinical Oncology Annual Meeting on June 4. The data reported add to the growing body of evidence in support of bevacizumab use to treat recurrent and newly-diagnosed ovarian cancer. Positive results from two bevacizumab (Avastin®) phase III [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4921689 Thu, 09 Jun 2011 23:15:13 +0100 4921689 http://www.medworm.com/index.php?rid=4902643&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F05%2F2011-asco-ec145-demonstrates-85-percent-improvement-in-progression-free-survival-for-treatment-of-platinum-resistant-ovarian-cancer%2F EC145, in combination with pegylated liposomal doxorubicin (Doxil®/Caelyx®) in patients with platinum-resistant ovarian cancer, met its primary endpoint by showing an 85 percent (2.3 month) improvement in median progression-free survival in the intent-to-treat population, and a 260 percent (4.0 month) improvement in a subset of folate receptor positive patients. The final EC145 phase 2 clinical study data were presented [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4902643 Mon, 06 Jun 2011 05:08:29 +0100 4902643 http://www.medworm.com/index.php?rid=4893809&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F03%2F2011-asco-entremed%25e2%2580%2599s-enmd-2076-demonstrates-clinical-activity-in-recurrent-platinum-resistant-ovarian-cancer-patients%2F EntreMed, Inc. announced that ENMD-2076 demonstrated clinical activity — a six-month progression free survival rate of 19% – when administered as a single agent to platinum drug-resistant recurrent ovarian cancer patients. The announcement is based upon interim phase 2 data presented today at the 2011 American Society of Clinical Oncology Annual Meeting.  EntreMed, Inc., a clinical-stage [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4893809 Sat, 04 Jun 2011 05:10:24 +0100 4893809 http://www.medworm.com/index.php?rid=4893810&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F03%2F2011-asco-matching-targeted-therapies-to-specific-tumor-gene-mutations-key-to-personalized-cancer-treatment%2F Customizing targeted therapies to each tumor’s molecular characteristics, instead of a “one-size-fits-all” approach by tumor type, may be more effective for some types of cancer, according to research presented today at the American Society of Clinical Oncology annual meeting by the M.D. Anderson Cancer Center. In patients with end-stage disease, matched patients achieved a 27% [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4893810 Sat, 04 Jun 2011 03:36:14 +0100 4893810 http://www.medworm.com/index.php?rid=4841885&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-genetic-biomarker-predicts-taxane-drug-induced-neuropathy%2F A new study has identified the first genetic biomarkers for taxane-induced peripheral neuropathy, a potentially severe complication of taxane chemotherapy that affects nerves in about one-third of patients with cancer receiving such treatment. ASCO Releases Studies From Upcoming Annual Meeting – Important Advances in Targeted Therapies, Screening, and Personalized Medicine The American Society of Clinical Oncology (ASCO) today highlighted [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841885 Thu, 19 May 2011 23:39:33 +0100 4841885 http://www.medworm.com/index.php?rid=4841886&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-novel-multi-targeted-agent-cabozantinib-xl184-has-significant-effect-on-several-advanced-solid-tumors%2F Cabozantinib (XL184) demonstrated high rates of disease control in patients with prostate, ovarian and liver cancers. The investigators concluded that cabozantinib exhibits clinical activity in ovarian cancer patients with advanced disease, regardless of prior platinum drug status, as reflected by the high rates of response.  ASCO Releases Studies From Upcoming Annual Meeting – Important Advances [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841886 Thu, 19 May 2011 21:53:46 +0100 4841886 http://www.medworm.com/index.php?rid=4841887&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2Fasco-2011-maintenance-therapy-with-parp-inhibitors-could-play-important-role-in-treatment-of-recurrent-ovarian-cancer%2F A randomized phase II clinical trial showed that the oral PARP inhibitor drug olaparib (AZD2281), given after chemotherapy, improved progression-free survival in women with the most common type of recurrent ovarian cancer. ASCO Releases Studies From Upcoming Annual Meeting – Important Advances in Targeted Therapies, Screening, and Personalized Medicine The American Society of Clinical Oncology (ASCO) today [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841887 Thu, 19 May 2011 18:03:58 +0100 4841887 http://www.medworm.com/index.php?rid=4841888&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F19%2F2011-asco-screening-with-ca-125-transvaginal-ultrasound-does-not-reduce-ovarian-cancer-death-rate-results-in-high-number-of-false-positives%2F Findings from a large, long-term study – the Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial – showed that using a CA-125 blood test and transvaginal ultrasound for early detection of ovarian cancer did not reduce the risk of dying from the disease, and resulted in a large number of false positives and related follow-up [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841888 Thu, 19 May 2011 15:56:18 +0100 4841888 http://www.medworm.com/index.php?rid=4841889&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F05%2F18%2F2011-asco-annual-meeting-abstracts-including-ovarian-cancer-made-publicly-available-today%2F More than 30,000 cancer specialists from around the world will gather at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest innovations in research, quality, practice and technology in cancer. More than 30,000 cancer specialists from around the world will gather at the 2011 American Society of Clinical Oncology (ASCO) [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4841889 Wed, 18 May 2011 22:43:10 +0100 4841889 http://www.medworm.com/index.php?rid=4615099&cid=t_142235_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fsurvivorship-planning-may-be-the-key-to-beating-cancer%2F2011.03.20 I am a poster child for why everyone who has had cancer needs to work with their doctor(s) to develop and implement a survivorship plan. Two of my four cancer-related diagnoses were found during routine screenings.  Two of my cancer-related diagnoses and one serious heart condition were almost certainly due to late effects of cancer treatment when I was young. Each was a complete surprise to me, and while there is evidence that predicts most of these occurrences, not one of my doctors used this literature to shape a plan for my post-treatment care. I was on my own.  My fear of yet another recurrence led me over time to cobble together a motley collection of oncologists (one for each body part) and other specialists (cardiologist, dermatologist, endocrinologist, and so forth) to watch ove... Better Health blogs http://www.medworm.com/rss/comments.php?id=4615099 Sun, 20 Mar 2011 14:00:54 +0100 4615099 http://www.medworm.com/index.php?rid=3816761&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F7n1Wk8OF9tg%2F In a sharply worded letter to the Centers for Medicare & Medicaid Services, the American Society of Clinical Oncology takes the federal agency to task for conducting a coverage review of the Provenge prostate cancer vaccine. You may recall that CMS unexpectedly disclosed plans for a National Coverage Analysis in late June in response to inquiries from regional Medicare programs about the novel therapy. Ever since, CMS has been bombarded with comments from patients, doctors and investors, among others. The vast majority express concern that CMS will somehow limit coverage next year, although a review of the $93,000 annual price tag per patient is not supposed to factor into the review (back story). In his letter, ASCO ceo Allen Lichter complains the reasoning given for the review is wa... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3816761 Tue, 03 Aug 2010 12:26:29 +0100 3816761 http://www.medworm.com/index.php?rid=3790702&cid=t_142235_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fthe-cancer-letter-reveals-rhodes-scholar-falsification-by-duke-cancer-researcher%2F2010.07.26 This is not good. Not good at all. Recently Paul Goldberg of The Cancer Letter reported on an investigation into Duke cancer researcher Anil Potti, M.D., and claims made that he was a Rhodes Scholar in Australia. The misrepresentation was made on grant applications to National Institutes of Health (NIH) and the American Cancer Society (ACS). The Cancer Letter, a $375 per year go-to newsletter on cancer research, funding, and drug development, has made this issue free at this PDF link. News & Observer higher education reporter Eric Ferreri has a nice overview of the situation. Potti has been placed on administrative leave by Duke, and the ACS has suspended payments on his grant and initiated their own investigation. (more…) *This blog post was originally published at Terr... Better Health blogs http://www.medworm.com/rss/comments.php?id=3790702 Mon, 26 Jul 2010 21:00:07 +0100 3790702 http://www.medworm.com/index.php?rid=3662673&cid=t_142235_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fhealth-news-how-big-medical-conferences-try-to-control-it%2F2010.06.14 In recent days, news readers/viewers/listeners have been bombarded with news from the big American Society of Clinical Oncology conference in Chicago. But how does some of this stuff become news? Read an excellent post by an excellent reporter, Ron Winslow of the Wall Street Journal, to see some of the crazy, ugly sausage-making that goes on in the manipulation of the media. In the example Winslow raises, what may be packaged as news really isn’t ”new” — which is often the case. *This blog post was originally published at Gary Schwitzer's HealthNewsReview Blog* (Source: Better Health) Better Health blogs http://www.medworm.com/rss/comments.php?id=3662673 Mon, 14 Jun 2010 18:00:23 +0100 3662673 http://www.medworm.com/index.php?rid=3644767&cid=t_142235_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fclinical-trials-accessing-the-medicines-of-tomorrow-today%2F2010.06.08 Reporting from the American Society of Clinical Oncology conference in Chicago, empowered patient Andrew Schorr discusses how long it can take before a study is presented at ASCO and the role of clinical trials in giving patients access to the medicines of tomorrow today. What’s Old is New at ASCO from Patient Power® on Vimeo. *This blog post was originally published at Andrew's Blog* (Source: Better Health) Better Health blogs http://www.medworm.com/rss/comments.php?id=3644767 Tue, 08 Jun 2010 16:00:55 +0100 3644767 http://www.medworm.com/index.php?rid=3617836&cid=t_142235_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Ffor-cancer-survivors-yoga-may-ease-sleeplessness-and-fatigue%2F2010.06.01 People who’ve been diagnosed cancer can be heartened by the results of a study that will be presented June 5 at the upcoming American Society of Clinical Oncology annual meeting. The researchers found that the practice of yoga helped cancer survivors improve sleep quality and reduce fatigue. The lead researcher, Dr. Karen Mustian, professor of Radiation Oncology and Community and Preventive Medicine at the University of Rochester in New York,  followed 410 patients who had already completed treatment for cancer but who experienced sleep disturbance that required medication. (more…) *This blog post was originally published at EverythingHealth* (Source: Better Health) Better Health blogs http://www.medworm.com/rss/comments.php?id=3617836 Tue, 01 Jun 2010 12:00:00 +0100 3617836 http://www.medworm.com/index.php?rid=3592409&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F9tRmMfqC4sQ%2F Welcome back, everyone. We hope your weekend was pleasant and restful. Now, of course, the routine returns. As always, we are brewing the mandatory cup of stimulation as we map out the week ahead. With meetings and deadlines looming, here are a few items to keep you abreast of events. Hope the days goes well and do stay in touch… Pfizer Gave Union ‘False Hope’ About Facility (The News-Journal) Pharmacists Want Compensation From Glaxo (Stuff.co.nz) Quintiles Lays Off No. Carolina Employees (Triangle Business Journal) ASCO Briefing Highlights Promising Data (PharmaTimes) Contract Pharmaceutical Closing NY Plant, Axing 260 Jobs (Associated Press) WHO Says EU Drug Seizures Were Improper (The Hindu) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3592409 Mon, 24 May 2010 11:53:08 +0100 3592409 http://www.medworm.com/index.php?rid=3590475&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F05%2F21%2Fasco-releases-studies-from-upcoming-2010-annual-meeting%2F Yesterday, the American Society of Clinical Oncology (ASCO) made available more than 4,000 medical abstracts which are publicly posted online at www.abstract.asco.org. A hyperlink to the 2010 ASCO Annual Meeting ovarian cancer abstracts is provided below.  The ASCO Annual Meeting will be held June 4-8, 2010 at McCormick Place in Chicago, Illinois. Yesterday, the American [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3590475 Sat, 22 May 2010 00:08:58 +0100 3590475 http://www.medworm.com/index.php?rid=3563958&cid=t_142235_87_f&fid=38368&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FDisruptiveWomenInHealthCare%2F%7E3%2FUHjGKILo-L8%2F By Archelle Georgiou. On Wednesday, the FDA suddenly decided to impose their regulatory authority on personalized genetic test kits after Walgreens and Pathway Genomics announced they’d be selling them in local pharmacies. But, what triggered this response from the FDA? Are they new? No. These kits have been available to consumers via the Web for 3 years. Have they been off the regulatory radar screen? No. As far back as 2008, the rapid emergence of genetic testing fueled the passage of GINA, a federal law prohibiting health insurers and employers from discriminating on the basis of genetic information. Have these companies been quietly launching their strategy and staying invisible? No. They have made major investments in marketing with an abundant amount of media coverage in women&... Disruptive Women in Health Care blogs http://www.medworm.com/rss/comments.php?id=3563958 Fri, 14 May 2010 11:57:24 +0100 3563958 http://www.medworm.com/index.php?rid=3494549&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Faw9XrFxnwoI%2F The Council of Medical Specialty Societies, which includes 32 physician groups with some 650,000 members, has adopted a new ethics code designed to limit the influence that drug and device makers have over patient care. Among the groups represented are the American College of Cardiology, the American Society of Clinical Oncology, the American Academy of Pediatrics and the American College of Physicians. In doing so, the CMSS addresses an issue that has roiled the pharmaceutical industry and attracted withering attention from consumer groups and government officials, who have increasingly complained that conflicts can skew patient treatment. In recent years, the concerns have led to scrutiny of freebies, continuing medical education, research grants and fees for speaking and consulting. In ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3494549 Thu, 22 Apr 2010 12:38:34 +0100 3494549 http://www.medworm.com/index.php?rid=2963293&cid=t_142235_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F11%2F04%2F%25c3%25a6terna-zentaris-lhrh-receptor-targeted-therapy-aezs-108-produces-positive-preliminary-results-in-advanced-stage-ovarian-cancer%2F Preliminary Phase II clinical study evaluation shows that primary efficacy endpoint has been met for patients with advanced-stage, platinum-resistant, taxane-pretreated ovarian cancer who were treated with the targeted therapy AEZS-108. Æterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase II study with its [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2963293 Wed, 04 Nov 2009 20:39:09 +0100 2963293 http://www.medworm.com/index.php?rid=1482289&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F302184559%2F A clinical trial of 1,125 lung cancer patients who were treated with ImClone Systems’s Erbitux and chemo lived about five weeks longer than patients treated with chemo alone, according to a study released at the American Society of Clinical Oncology meeting. Here is the abstract. The results could make Erbitux, which is currently approved for colon tumors and head and neck cancer, the preferred therapy for half of non-small cell lung cancer patients who can’t take Genentech’s Avastin due to side effects. Patients getting Erbitux plus standard chemo had a median survival of 11.3 months, compared with 10.1 months for those given only chemo. In all, 36.3 percent responded to the combo, compared with 29.2 percent who improved after getting only chemo. Erbitux increased survi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1482289 Sat, 31 May 2008 15:58:57 +0100 1482289 http://www.medworm.com/index.php?rid=1480945&cid=t_142235_136_f&fid=36051&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F301292159%2F What: ASCO 2008 Annual Meeting When: May 30-June 3, 2008 Where: McCormick Place — Chicago, Illinois USA The ASCO (American Society of Clinical Oncology) Annual Meeting is considered the premier educational and scientific event in the oncology community. Abstracts from the said meeting is now available online. Tags: American Society of Clinical Oncology, ASCO, ASCO Annual Meeting, Chicago, clinical oncology, oncologyShare This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1480945 Fri, 30 May 2008 14:29:52 +0100 1480945 http://www.medworm.com/index.php?rid=1478214&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F300773805%2F Potential advances in the treatment of lung cancer will be a major focus as the American Society of Clinical Oncology gets under way in Chicago on Friday. In particular, ImClone Systems will unveil long-awaited results from a pivotal trial of its Erbitux drug, in combination with chemotherapy, in patients with advanced nonsmall cell lung cancer, Reuters writes. The drugmaker has already said its Flex study met its main goal of boosting survival, but what is not clear is how much longer patients were shown to live. “The Flex study will be one of the most important presentations at ASCO,” Roy Herbst, chief of thoracic oncology at Houston’s MD Anderson Cancer Center, tells Reuters. “Lung cancer doctors and patients would like to know more details.” The Chicago m... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1478214 Thu, 29 May 2008 20:28:10 +0100 1478214 http://www.medworm.com/index.php?rid=1379581&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F272347252%2F A year after approval of the Provenge prostate-cancer vaccine was delayed by the FDA, a determined group of prostate-cancer patients - and some investors, too - plan to stage a series of nationwide protests that will include the largest annual gathering of oncologists, two organizers tell us. The events are planned by a non-profit called Care To Live, which is battling the FDA in court in what has, so far, been an unsuccessful attempt to force the agency to reverse course. The specter of a protest is likely to unnerve the American Society of Clinical Oncology, because threats were allegedly made at last year’s event against two cancer docs who were dissenters on the FDA panel that recommended approval for Provenge. After the FDA panel meeting, those two docs - Howard Scher of Sloan-K... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1379581 Thu, 17 Apr 2008 18:28:50 +0100 1379581 http://www.medworm.com/index.php?rid=897085&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F160699554%2F That’s the word from Jim Reddoch, a biotech analyst at Friedman Billings Ramsey, after Medicare wrote doctor groups that it remains unconvinced its recent decision to scale back reimbursement for Amgen’s Aranesp was inappropriate. The letter from the Centers for Medicare and Medicaid Services was written in response to protests filed by the American Society of Clinical Oncology, the American Society of Hematology and US Oncology, a healthcare network. “The groups claimed CMS misinterpreted the existing data supporting Aranesp in patients with hemoglobin levels above 10 grams per deciliter,” Reddoch writes in an investor note. “In CMS’ response this morning, CMS is unconvinced it needs to reconsider, saying no new evidence has been brought to light, nor i... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=897085 Mon, 24 Sep 2007 17:50:28 +0100 897085 http://www.medworm.com/index.php?rid=818942&cid=t_142235_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F147467104%2F Conflicts of interest are all the rage these days. And for good reason. Understanding the factors influencing decisions - which finding may be emphasized, which paper gets published, which medication is endorsed - is increasingly of concern. So a handful of researchers, with NIH backing, measured financial ties on display at two meetings of the American Society of Clinical Oncology. They perused 3,529 abstracts and 25,416 authors in 2004 and 3,556 abstracts and 26,181 authors in 2005. Their findings, which were published in the Journal of Clinical Oncology: In 2004 and 2005, 23 percent of abstracts had one or more authors with a personal financial interest. More than 75 percent of all personal financial interests were valued at less than $10,000. On one hand, 23 percent may be seen as high... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=818942 Thu, 23 Aug 2007 21:18:43 +0100 818942